# Advanced Enzyme Technologies share price today (Advanced Enzyme Technologies Ltd, NSE: ADVENZYMES)

> Advanced Enzyme Technologies share price today: ₹274.25 at the NSE close on 3 November 2026, down 11.0% in a year. Advanced Enzyme Technologies (NSE: ADVENZYMES) is worth ₹3,066 crore, trades at a P/E of 18.9 and has closed between ₹248.35 and ₹376.50 over the past 52 weeks. > Advanced Enzyme Technologies Ltd's earnings have grown faster than its share price. Earnings per share grew +28.6% in a year while the price moved −11.0%. ADVENZYMES · Seeds/Tissue Culture/Bio Technology · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/advanced-enzyme-technologies-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹274.25 (−11.0% in a year)
- P/E: 18.9× (lower than 85% of the last 10 years)
- Revenue (Sep 2026): ₹215 Cr (+16.2% on a year ago)
- Profit (Sep 2026): ₹51.0 Cr (+13.3% on a year ago)
- Operating margin: 34.0% (+1.0 points on a year ago)
- ROCE: 14%, FY26
- Profit that came in as cash: 99%, last 3 years

The main question: yearly earnings per share moved +28.6% while the share price moved −11.0%. ## What is the Advanced Enzyme Technologies share price today? Advanced Enzyme Technologies Ltd's share price was ₹274.25 at the close on 3 November 2026. It has been falling for 10 weeks. That is 10.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹248 and ₹377, and at that close it sat 20% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 20 weeks running. Over the last 10 years the share price moved −4% while the NIFTY 500 moved +201%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Advanced Enzyme Technologies this quarter? Three changes stood out: indian funds and insurers (DIIs) cut their stake for 5 quarters in a row, revenue up on a year earlier for 8 quarters in a row and best operating margin in 10 quarters. 1. Indian funds and insurers (DIIs) cut their stake for 5 quarters in a row From 8.5% to 1.9% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 8 quarters in a row In the September 2026 quarter revenue was ₹215 crore, +16.2% on a year earlier. 3. Best operating margin in 10 quarters Operating margin was 34% in the September 2026 quarter, against 33% a year earlier. ## What are Advanced Enzyme Technologies' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Advanced Enzyme Technologies reported revenue of ₹215 crore, up 16.2% from ₹185 crore a year earlier, and a profit of ₹51.0 crore, up 13.3% from ₹45.0 crore. ### Advanced Enzyme Technologies results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹215 crore | ₹185 crore | +16.2% |
| Profit | ₹51.0 crore | ₹45.0 crore | +13.3% |
| Earnings per share | ₹4.31 | ₹3.87 | +11.4% |
| Operating margin | 34.0% | 33.0% | +1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 12 August 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Advanced Enzyme Technologies share price history? Advanced Enzyme Technologies closed at ₹274.25 on 3 November 2026, down 11.0% from ₹308.05 a year earlier (31 October 2025) and down 24.7% over five years. Its highest weekly close since August 2016 was ₹538.05 on 20 September 2024. ### Advanced Enzyme Technologies share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹248.35 | +10.4% |
| 1 month ago · 1 Oct 2026 | ₹274.25 | 0.0% |
| 6 months ago · 30 Apr 2026 | ₹347.70 | −21.1% |
| 1 year ago · 31 Oct 2025 | ₹308.05 | −11.0% |
| 3 years ago · 3 Nov 2023 | ₹308.40 | −11.1% |
| 5 years ago · 4 Nov 2021 | ₹364.15 | −24.7% |
| 10 years ago · 4 Nov 2016 | ₹378.08 | −27.5% |
| Earliest weekly close in our records · 5 Aug 2016 | ₹284.79 | −3.7% |
| Highest weekly close since August 2016 · 20 Sep 2024 | ₹538.05 | −49.0% |
| Lowest weekly close since August 2016 · 20 Mar 2020 | ₹112.85 | +143.0% |
| 52-week high (weekly close) · 4 Jun 2026 | ₹376.50 | −27.2% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹248.35 | +10.4% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (542 weekly closes from 5 August 2016 to 3 November 2026.)

## What is the latest news on Advanced Enzyme Technologies? 3 Nov 2026: Advanced Enzyme Technologies closed at ₹274.25, up 10.4% on the week and up 0.0% on the month. Results for July to September 2026: Revenue up 16.2% and profit up 13.3% on a year earlier. ### Earlier

- 12 Aug 2026: Advanced Enzyme Technologies held its results call for April to June 2026. Management guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end. - 24 Jul 2026: ex-date for a dividend of ₹1.35 a share. ## What dividend does Advanced Enzyme Technologies pay? Advanced Enzyme Technologies paid ₹1.35 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.49% at the ₹274.25 close on 3 November 2026. The last was a dividend of ₹1.35 a share, ex-date 24 July 2026. ### Advanced Enzyme Technologies dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 24 Jul 2026 | ₹1.35 | Dividend | same day |
| 23 Jul 2025 | ₹1.20 | Dividend | same day |
| 16 May 2025 | ₹4 | Interim | 17 May 2025 |
| 18 Jul 2024 | ₹1.10 | Dividend | same day |
| 17 May 2024 | ₹4 | Interim | 18 May 2024 |
| 4 Aug 2023 | ₹1 | Dividend | 5 Aug 2023 |
| 19 May 2023 | ₹4 | Interim | 20 May 2023 |
| 11 Aug 2022 | ₹1 | Dividend | 12 Aug 2022 |
| 31 Aug 2021 | ₹0.90 | Dividend | 1 Sep 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Advanced Enzyme Technologies Ltd paid out 36% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Advanced Enzyme Technologies management say on the latest results call? On the call for April to June 2026, held on 12 August 2026, Advanced Enzyme Technologies' management guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end. > “We are trying to revamp and change our business model in such a way that we have sustained growth while our margins remain intact.”
> Mukund Kabra, on the call for April to June 2026

### What management guided

- Incremental sales reversal expected to normalise in July to September 2026 after shipment delivery. - Operating margin expected to return to approximately 30% for FY27 and remain within 30-32%. - Biocatalysis expected to deliver good growth in H2FY27; protein-hydrolysis sales to develop across subsequent quarters. - Approximately ₹123 crore consolidated capital spending, including ₹20 crore normal capital spending and ₹50 crore R&D; capacity spending may begin after next-quarter review and the R&D facility may become functional next quarter. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5616/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 12 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What could change the Advanced Enzyme Technologies story? What are the risks? Consolidated operating margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below ₹500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. ### The main risks

- US market structural weakness and tariff absorption: US revenue constrained by tariffs and consumer softness; FY27 US growth guided at 8-10%. ✓ fact
- Operating margin compression from input and energy costs: April to June 2026 operating margin compressed to 27%; FY27 recovery to 30-32% dependent on operational leverage. ⚠ estimate

(Our read after the April to June 2026 results, written 22 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Advanced Enzyme Technologies' next results? When Advanced Enzyme Technologies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Q2 revenue print: verify sales-reversal normalisation and whether the robust pipeline produces the expected momentum improvement. - What to check (from the call)
- Q2 revenue print: verify sales-reversal normalisation and whether the robust pipeline produces the expected momentum improvement. - Operating margin: check recovery toward the normal framework as operational efficiency offsets power and fuel pressure. - US business: track branded-ingredient conversion, customer retention and visibility after geopolitical and hiring constraints. - R&D facility and fermentation capacity: check commissioning, next-quarter expansion decision and new-molecule throughput. ## Which stock lists is Advanced Enzyme Technologies on? Advanced Enzyme Technologies is not on any of our India lists this week. ## Is Advanced Enzyme Technologies profitable? Advanced Enzyme Technologies Ltd earned ₹51.0 Cr of net profit in the Sep 2026 quarter, +13.3% on the same quarter a year earlier. Full-year FY26 profit was ₹174 Cr. Over 10 years profit has grown 8.5% a year on average. That is 23.7% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr. For the full year, FY26 profit was ₹174 Cr (+29.9% on the year before). Why profit moved: revenue changed +16.2% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +21.9% and revenue +10.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported. FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much revenue does Advanced Enzyme Technologies make, and is it growing? Advanced Enzyme Technologies Ltd reported ₹215 Cr of revenue in the Sep 2026 quarter, +16.2% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 9.8% a year on average. The last full year, FY26, came in at ₹746 Cr. The last four reported quarters add to ₹782 Cr. FY26 revenue was ₹746 Cr, +17.1% on the year before. Recent pace: the last four quarters grew +10.7% on average, against 9.8% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +12.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +17.9%, against +12.8% a year (accelerating). FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported. FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Advanced Enzyme Technologies keep? Advanced Enzyme Technologies Ltd's operating margin was 34.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 21.0% and 47.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.1 percentage points on the year while gross margin changed −2.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. FY27-Q1. revenue ₹192 Cr and profit ₹39 Cr as reported. FY27-Q2. revenue ₹215 Cr and profit ₹51 Cr as reported. Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters. ## Is Advanced Enzyme Technologies' profit turning into cash? Over the last 3 years, 99% of Advanced Enzyme Technologies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹157 Cr of operating cash against ₹174 Cr of profit. After ₹82.0 Cr of spending on assets, ₹75.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 99% of profit came in as cash: the cash cycle got 22 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 1.6× depreciation over three years. The next section checks what that spending is building. ## Where does Advanced Enzyme Technologies' cash go? Advanced Enzyme Technologies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 331 days in FY26, down from 353 days in FY21. It spent ₹184 Cr on assets over the last 3 years. Customers take 71 days to pay, and stock sits for 335 days on average. Why this happened. Consolidated capex plan includes ₹50 Cr for R&D expansion in FY27 (). Modernized facility triples development bandwidth for 15-20 active pipeline molecules. Confidence capped at 0.40 due to timeline slippages (). At FY26 sales of ₹746 Cr, each day of that cycle ties up about ₹2.0 Cr, so roughly ₹677 Cr is tied up in the business at any time. FY26: customers took 71 days to pay and stock sat for 335 days, about 11.0 months of sales sitting as stock, for a full cycle of 331 days, shorter than FY21's 353. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 335 days. Customers pay about 71 days after that. Suppliers are paid at 76 days. Together that makes the 331-day cycle. Spending on assets: ₹184 Cr over the last 3 years, against ₹112 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹51.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Advanced Enzyme Technologies' P/E ratio, and how does it compare with its own history? Advanced Enzyme Technologies Ltd's P/E is 18.9×, near the low end of its own history: it has been lower only 15% of the time. Its usual P/E (the middle reading) is 27.6×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹15.26. Why the multiple is where it is: over the past year earnings per share moved +28.6% while the price moved −11.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −5.5% a year; about +1.0% a year came from earnings growth and about −6.5 percentage points from the multiple (the market paying less); over 10 years the price moved −3.2% a year; about +4.7% a year came from earnings growth and about −7.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 4.0% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the Advanced Enzyme Technologies share price assume? Worked out from its price on 26 August 2026, Advanced Enzyme Technologies Ltd's share price assumed profit growth of about 12.1% a year. Over the past 10 years its profit actually grew 8.5% a year. Today its P/E is 18.9×, lower than 85% of its own last 10 years. This is a one-day reading, taken on 26 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Advanced Enzyme Technologies business getting better or worse? Advanced Enzyme Technologies Ltd's business is turning around. Profit growth has swung from −1.5% at its low to +17.9%, rising from a low 5 quarters ago, with ROCE steady at 14.0%. This is based on 9 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the Advanced Enzyme Technologies story, and has it been checked? Advanced Enzyme Technologies Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: MID EXPANSION. What is proven. See the research file

What is not proven yet. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. What would change our mind. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. The test written in advance. Consolidated EBITDA margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below Rs 500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. Measured by: the thesis as written as stated by the next result. Lever 5 · Regulatory approval: building. EFSA novel-food dossier filed for Serratiopeptidase, approval expected during FY27 (). Product already represents 23% of total revenue (). EU approval adds a new geographic revenue pool to an established commercial base. What proves it keeps working: EU Serratiopeptidase novel-food approval. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Advanced Enzyme Technologies management deliver what it promised? What Advanced Enzyme Technologies Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Intermediates Initiative Abandoned · 12 August 2026. The latest call reverses the February 2026 position that management was still pursuing the intermediates opportunity and expected to establish a foothold. This is a strategic change in a segment management still described as high-growth, but the latest call does not explain why the initiative was abandoned. Nashik R&D Center Timeline Slippage · 12 May 2026. Both the Nov 2025 and Feb 2026 calls committed to full commissioning of the Nashik R&D center by end of Q2 FY27 (September 2026), with the Nov 2025 call additionally promising partial activation by March 2026. The May 2026 call makes no mention of partial operations having started and now only guides full operationalization to the latter half of FY27, an unexplained delay past the September 2026 milestone stated explicitly across both prior calls. US Business Outlook Reversal · 12 May 2026. In the Feb 2026 call, management expressed explicit optimism about US recovery, stating increased inquiries and interest would reflect positively in FY26 performance itself. The May 2026 call, however, reports US Q4 FY26 revenue down 11% year-on-year and characterizes FY27 as a very challenging year with no clear explanation of what deteriorated in the roughly three months between the two calls. R&D Center Commissioning Delay · 4 February 2026. In the November 2025 call, management guided that the new R&D center would likely be capitalized and partially active by the end of the fiscal year (March 2026). However, in the February 2026 call, the timeline was pushed back significantly to the end of the second quarter of the coming year (approx. September 2026) without elaborating on the cause of the delay. Earlier call (Nov 2025): “Probably, by the end of the March, it should have some kind of shape... It will partially become active by the end of this fiscal year.” Later call (Feb 2026): “Commissioning should be around the end of the second quarter of the coming year.”

Every quote above is taken word for word from the company’s own earnings calls. ## What is Advanced Enzyme Technologies management's track record? Good multi-year quality offset by near-term slippage. ### Regulatory and governance record

No SEBI/CBI/ED action or fraud surfaced; 0% promoter pledging. 0% Promoter shares pledged

Sources:

- [icicidirect.com](https://www.icicidirect.com)
- [pocketful.in](https://www.pocketful.in/stocks/)
- [economictimes.indiatimes.com](https://economictimes.indiatimes.com)

(Checked 21 July 2026.)

## How much does Advanced Enzyme Technologies earn on its capital? Advanced Enzyme Technologies Ltd earned a ROCE of 14% in FY26. That is up from a low of 12% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 23.3% net margin and 0.41× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 23.3% net margin × 0.41× asset turnover × 1.12× leverage (assets divided by equity) ≈ 10.7% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.0% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Advanced Enzyme Technologies have too much debt? Advanced Enzyme Technologies Ltd had ₹32.0 Cr of borrowings against ₹1,632 Cr of equity in FY26, so its debt is 0.02× its equity. Its operating profit is 58 times its interest bill. Over 5 years borrowings went from ₹23.0 Cr to ₹32.0 Cr. Over the last 3 of those years it spent ₹184 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.0% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Advanced Enzyme Technologies shareholding pattern? Foreign institutions raised their stake in Advanced Enzyme Technologies Ltd by 14.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 26.6% of the company. Domestic institutions moved −6.1 points over the same period, to 1.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +14.0 points over 8 quarters, to 26.6%; Domestic institutions: −6.1 points over 8 quarters, to 1.9%; Promoters: +0.6 points over 8 quarters, to 43.6%. Why the owners changed: foreign institutions moved +14.0 points and domestic institutions −6.1 points over 8 quarters, while promoters moved +0.6 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Advanced Enzyme Technologies from balance-sheet trouble? For Advanced Enzyme Technologies Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Advanced Enzyme Technologies rank in its industry? 53.6 out of 100, rank 1 of 3 in Seeds/Tissue Culture/Bio Technology, with 79% of the evidence available. Advanced Enzyme Technologies Ltd scores 53.6 out of 100 against the 3 companies it is compared with in Seeds/Tissue Culture/Bio Technology, ranking 1. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.2 + 15.5 + 12.5 + 4.4 = 53.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Advanced Enzyme Technologies compared with? Advanced Enzyme Technologies ranks 1 of 3 Seeds/Tissue Culture/Bio Technology companies on the 4-Factor Sector Score, with 53.6 out of 100. 1. Advanced Enzyme Technologies Ltd this page ADVENZYMES · quiet · Evidence leans up · 79% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.2/35 · Revenue 10.6% · Profit 17.9% · Operating margin change 1 points · 95% evidence Capital efficiency 15.5/25 · ROCE 14% · Operating margin 34% · 76% evidence Valuation 12.5/20 · P/E 18.2× · PEG n/a · 35% evidence Relative strength 4.4/20 · Lead over its industry -0.1% · Lead over NIFTY 500 -10.1% · 1 year -14.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 21.2 + 15.5 + 12.5 + 4.4 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Bombay Super Hybrid Seeds Ltd](https://www.sectoralpha.in/stocks/bombay-super-hybrid-seeds-ltd) BSHSL · turning · Evidence leans down · 97% evidence 49.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.2/35 · Revenue 22.4% · Profit 3.9% · Operating margin change -10.5 points · 100% evidence Capital efficiency 12.8/25 · ROCE 16% · Operating margin 5% · 100% evidence Valuation 11.1/20 · P/E 30.3× · PEG 2.15 · 85% evidence Relative strength 13.9/20 · Lead over its industry 3.8% · Lead over NIFTY 500 -6.5% · 1 year -32% · 100% evidence · 2 of 12 weeks ahead Exact sum: 11.2 + 12.8 + 11.1 + 13.9 = 49 · What this means: Relative strength against the index is -6.5%, and revenue and profit growth are weak. 3. [Rossari Biotech Ltd](https://www.sectoralpha.in/stocks/rossari-biotech-ltd) ROSSARI · quiet · Evidence leans down · 97% evidence 47.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 19.8% · Profit 11.7% · Operating margin change 0 points · 100% evidence Capital efficiency 13.4/25 · ROCE 13.3% · Operating margin 12% · 100% evidence Valuation 14.9/20 · P/E 14.5× · PEG 1.42 · 85% evidence Relative strength 0.0/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -17.4% · 1 year -37.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.4 + 13.4 + 14.9 + 0 = 47.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Seeds/Tissue Culture/Bio Technology](https://www.sectoralpha.in/sectors/seeds-tissue-culture-bio-technology), all 3 compared on one page. ## Which companies are close to Advanced Enzyme Technologies in size? Advanced Enzyme Technologies is the largest of 3 Seeds/Tissue Culture/Bio Technology companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Rossari Biotech and Bombay Super Hybrid Seeds. ### Seeds/Tissue Culture/Bio Technology companies close in size

1. Advanced Enzyme Technologies Ltd ₹2,951 crore
2. [Rossari Biotech Ltd](https://www.sectoralpha.in/stocks/rossari-biotech-ltd) ₹2,212 crore
3. [Bombay Super Hybrid Seeds Ltd](https://www.sectoralpha.in/stocks/bombay-super-hybrid-seeds-ltd) ₹873 crore

[All 3 Seeds/Tissue Culture/Bio Technology companies, largest first](https://www.sectoralpha.in/sectors/seeds-tissue-culture-bio-technology#all-companies)

### Companies close in size in other industries

1. [Indostar Capital Finance Ltd](https://www.sectoralpha.in/stocks/indostar-capital-finance-ltd) ₹2,960 crore · Finance & Investments - CV Finance
2. [Ashika Credit Capital Ltd](https://www.sectoralpha.in/stocks/ashika-credit-capital-ltd) ₹2,952 crore · Finance - Investment Bankers
3. Advanced Enzyme Technologies Ltd ₹2,951 crore
4. [Axis Solutions Ltd](https://www.sectoralpha.in/stocks/axis-solutions-ltd) ₹2,947 crore · Engineering - Light - General
5. [Jaykay Enterprises Ltd](https://www.sectoralpha.in/stocks/jaykay-enterprises-ltd) ₹2,947 crore · Aerospace & Defence - Equipments

## What else do people ask about Advanced Enzyme Technologies? ### What is Advanced Enzyme Technologies's share price today? Advanced Enzyme Technologies Ltd's share price is ₹274.25, −11.0% over the past year. The whole company is worth ₹3,066 Cr on the market. In the last 52 weeks it traded between ₹248 to ₹377; today it is 20% of the way up from the low, 10.5% below its 200-day average (as of 3 November 2026). ### What were Advanced Enzyme Technologies's latest quarterly results? Advanced Enzyme Technologies Ltd reported revenue of ₹215 Cr and net profit of ₹51.0 Cr for the Sep 2026 quarter. Revenue rose 16.2% and profit rose 13.3% compared with a year earlier. Earnings per share were ₹4.31. The operating margin was 34.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Advanced Enzyme Technologies's market cap? Advanced Enzyme Technologies Ltd's market capitalisation is ₹3,066 Cr at a share price of ₹274.25. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Advanced Enzyme Technologies performing? Advanced Enzyme Technologies Ltd's share price has been falling for 10 weeks. In its latest quarter, revenue rose 16.2% and profit rose 13.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 20 weeks running (as of 3 November 2026). ### Will Advanced Enzyme Technologies's share price go up? This page does not forecast Advanced Enzyme Technologies Ltd's share price. What it shows instead: the share price is ₹274.25, and it has been falling for 10 weeks. Its P/E of 18.9× is higher than 15% of its own last 10 years (as of 3 November 2026). ### Where is Advanced Enzyme Technologies in its business cycle? Advanced Enzyme Technologies Ltd's FY26 operating margin was 31.0%, against a 13-year range of 21.0% to 47.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 34.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Advanced Enzyme Technologies story? The main question: yearly earnings per share moved +28.6% while the share price moved −11.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Advanced Enzyme Technologies a stock worth studying right now? What the numbers show: Advanced Enzyme Technologies Ltd's earnings have grown faster than its share price. Earnings per share grew +28.6% in a year while the price moved −11.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Advanced Enzyme Technologies share price forecast for 2026? What management itself guided: FY27 consolidated revenue growth in double digits; US business growth not expected to exceed approximately 8-10%, with approximately 8% by year-end. What would change the story: Consolidated operating margin remaining below 28% for two consecutive quarters alongside a sustained contraction in Human Healthcare international sales below ₹500 million per quarter, confirming structural loss of global pricing power rather than transient tariff and energy cost headwinds. ### Where does this page get Advanced Enzyme Technologies' management information? From Advanced Enzyme Technologies' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. This is research, not advice. We’re not SEBI-registered.